A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF BEMNIFOSBUVIR (BEM) AND RUZASVIR (RZR) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
- Registry ID
- AT-01B-004
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ATEA PHARMACEUTICALS INC
- Start date
- 2024-07-12
- Completion date
- 2025-01-24
- Last update
- 2023-05-10
Conditions
Related clinical trials
- PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF BEMNIFOSBUVIR-RUZASVIR FIXED-DOSE COMBINATION (BEM/RZR FDC) VERSUS SOFOSBUVIR-VELPATASVIR FIXED-DOSE COMBINATION (SOF/VEL FDC) IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
- SAFETY, TOLERABILITY, AND OUTCOMES OF VELPATASVIR/SOFOSBUVIR IN TREATMENT OF CHRONIC HEPATITIS C VIRUS DURING PREGNANCY (STORC):A SINGLE-ARM, SINGLE-CENTER, OPEN LABEL PHASE 1 STUDY OF A 12-WEEK COURSE OF SOF/VEL IN 10 HCV-INFECTED PREGNANT WOMEN.
- A PHASE II, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE COMBINATION REGIMENT OF MK-3682B (MK-5172 + MK-3682 + MK-8408 FIXED DOSE COMBINATION (FDC)) IN SUBJECTS WITH CHRONIC HCV GT1 OR GT3 INFECTION WHO HAVE FAILED A DIRECT ACTING ANTIVIRAL REGIMEN
- A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN RENALLY-IMPAIRED ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 ¿ 6 INFECTION (EXPEDITION-5)
- A PHASE 2, OPEN-LABEL CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF 12 WEEKS OF THE COMBINATION REGIMEN OF MK-3682 + MK-8408 IN SUBJECTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION
- A PHASE IA/IB STUDY ASSESSING SINGLE AND MULTIPLE DOSES OF CDI-31244, A NON-NUCLEOSIDE INHIBITOR IN HEALTHY AND HEPATITIS C VIRUS-INFECTED SUBJECTS
View on source registry